Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy—Applying Real-world Data to Clinical Trial Emulation

Narayan, Vivek

doi:10.1001/jamanetworkopen.2021.31429

JAMA Netw Open

2021

DOI: 10.1001/jamanetworkopen.2021.31429

|View full text |Cite

Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy—Applying Real-world Data to Clinical Trial Emulation

Vivek Narayan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RWD studies to date have generated different and sometimes contradictory results. 28 Among RWD studies showing decreased CVE with antagonists, Davey and Kirby 20 looked at 9,081 patients from the UK primary care setting and found decreased CVE with antagonists (RR, 0.39). In this study, only 1% (101/9,081) of patients were treated with antagonists, a third switched to agonists, and time on treatment was not collected.…”

mentioning

confidence: 99%

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Tisseverasinghe

Tolba

Saad

et al. 2022

JCO

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Tisseverasinghe

Tolba

Saad

et al. 2022

JCO

View full text Add to dashboard Cite

show abstract

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Zhou,

Alerasool,

Kishi

et al. 2024

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

Poon,

Tan,

Chan

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAndrogen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testosterone is associated with an increased risk of cardiometabolic syndrome. This highlights the urgency of multidisciplinary efforts to address the cardiometabolic risk of anticancer treatment in men with PCa.MethodsTwo professional organizations invited five urologists, five clinical oncologists, and two cardiologists to form a consensus panel. They reviewed the relevant literature obtained by searching PubMed for the publication period from April 2013 to April 2023, to address three discussion areas: (i) baseline assessment and screening for risk factors in PCa patients before the initiation of ADT and AR axis-targeted therapies; (ii) follow-up and management of cardiometabolic complications; and (iii) selection of ADT agents among high-risk patients. The panel convened four meetings to discuss and draft consensus statements using a modified Delphi method. Each drafted statement was anonymously voted on by every panelist.ResultsThe panel reached a consensus on 18 statements based on recent evidence and expert insights.ConclusionThese consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy—Applying Real-world Data to Clinical Trial Emulation

Cited by 3 publications

References 7 publications

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

Contact Info

Product

Resources

About